leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences unveils plans to raise US$57.25mln from US investors

The new cash will be used to advance three drug programmes

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it plans to raise a gross US$57.25mln from US investors to fund work on three separate drug programmes.

Just over 11mln new American depositary shares are being issued at US$5.20 each as part of the fundraiser, organised by ThinkEquity.

The proceeds will be used “advance the clinical development” of Foralumab, its promising fully-human anti-CD3 monoclonal antibody.

Cash will also be deployed to initiate trials of its other key drug Milciclib to treat a form of liver cancer called hepatocellular carcinoma (HCC) and to “expedite clinical development” of TZLS-501 for coronavirus (COVID-19).

There is a lot of excitement around Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.

The company will be shortly initiating phase II studies with an orally-administered drug for Crohn’s Disease and a nasally-administered derivative for progressive multiple sclerosis.

Tiziana said the phase II compound has potential application in a wide range of other autoimmune and inflammatory diseases, such as type-1 diabetes, inflammatory bowel disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

On Friday, Tiziana’s shares soared after it submitted a patent application covering the potential use of nasally-administered and orally taken Foralumab for the treatment of COVID-19 either alone or in combination with other antiviral drugs.

The methods of delivering the fully human anti-CD3 monoclonal antibody (mAb) could potentially modulate or stimulate the immune system to suppress cytokine storms and therefore reduce respiratory failure in coronavirus patients, the company said.

Its researchers believe a combination with other anti-viral drugs could improve efficacy.

Meanwhile, the ability to inhale Foralumab or take it by mouth overcomes the severe toxicities sometimes associated with the intravenous delivery of rival human anti-CD3 monoclonal antibodies.

Quick facts: Tiziana Life Sciences PLC

Price: 128.75 GBX

AIM:TILS
Market: AIM
Market Cap: £248.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

2 days, 5 hours ago

2 min read